In a recent study published in The Lancet Respiratory Medicine, researchers determined the evolution of health outcomes in individuals hospitalized due to acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Wuhan, purchasing indomethacin China. They also tracked the recovery status of these coronavirus disease 2019 (COVID-19) survivors for up to two years.
About the study
In the current longitudinal cohort study, researchers recruited individuals hospitalized due to COVID-19 in the Jin Yin-tan hospital of Wuhan, China, and later discharged between January 7 and May 29, 2020.
The team divided the study participants into three groups based on the infection severity scale. While patients in the scale 3 group did not need supplemental oxygen, those in the scale 4 received supplemental oxygen, and the group of patients in the scale 5 to 6 required high-flow nasal cannula or invasive or non-invasive mechanical ventilation.
The researchers estimated the correlation coefficients between different symptoms in COVID-19 survivors at three-time points, six months, 12 months, and two years after the symptom onset, and presented them as a heatmap.
The control group individuals were age and sex-matched to the test subjects. They had the same underlying comorbidities but no history of COVID-19. The researchers assessed the same parameters, including modified British Medical Research Council (mMRC) dyspnoea scale and HRQoL for the control group.
They performed laboratory tests, a six-minute walking distance (6MWD) test, and a series of questionnaires to assess each individual’s symptoms, including mental health, health-related quality of life (HRQoL), and health-care usage after hospital discharge. The researchers also compared the lung function of COVID-19 survivors in the three study groups and between COVID-19 survivors and their matched controls using a stringent Bonferroni correction. They set the α threshold for the former comparison at 5·56×10–³ and the latter at 0·0167.
For statistical analyses of the association between long COVID symptoms and health outcomes at a two-year follow-up visit, the team used multivariable-adjusted logistic regression models and generalized linear regression models for categorical and continuous outcomes.
Furthermore, the team used the χ² test, Kruskal-Wallis test, or Fisher’s exact or Mann-Whitney U tests to draw comparisons between the clinical and demographic characteristics of three study groups, as deemed necessary.
In total, 2469 COVID-19 patients were discharged from Jin Yin-tan Hospital between January 7 and May 29, 2020, of which 1192 COVID-19 survivors completed assessments at the three follow-up visits. However, only 1119 individuals attended the in-person interview two years after the infection. The average age of COVID-19 survivors at the time of hospital discharge was 57 years, and 46% of them were women.
Fatigue and muscle weakness were the most frequent sequelae symptoms in the majority of COVID-19 survivors. The symptom frequency diminished to 68% and 55% at six months and two years, respectively.
The proportion of COVID-19 survivors with an mMRC score of at least one was 26% at six months but reduced to 14% at two years. HRQoL, especially in terms of anxiety or depression, continued to improve across all the study groups. Accordingly, the proportion of COVID-19 survivors with symptoms of anxiety or depression decreased from 23% to 12% from six months to two years.
In the three study groups with varying initial disease severity, the proportion of COVID-19 survivors with a 6MWD less than the lower limit of the normal range declined continuously. Notably, 89% of COVID-19 survivors returned to work after two years.
Survivors with persistent COVID-19 symptoms at two years had lower HRQoL. Additionally, they were not fit to exercise, had mental health issues, and used more health-care support after discharge than survivors without such symptoms. Compared to controls, COVID-19 survivors suffered more from pain, discomfort, as well as anxiety, and depression at two years.
Additionally, 65% of those who had received respiratory support during hospitalization had lung diffusion impairment, while only 36% of controls faced this problem. Likewise, 62% of such patients suffered from reduced residual volume and 39% from total lung capacity issues. Conversely, only 20% and 6% of controls faced reduced residual volume and total lung capacity issues.
The study data demonstrated that the majority of COVID-19 survivors showed significantly improved physical and mental health outcomes, and a staggering 89% of them even returned to work after two years. However, the burden of sequelae symptoms remained high; therefore, they had a lower health status than the general population. Indeed, there is an urgent need to intervene and curb the risk of long COVID among patients hospitalized due to COVID-19.
- Huang, L. et al. (2022) "Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study", The Lancet Respiratory Medicine. doi: 10.1016/s2213-2600(22)00126-6. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00126-6/fulltext
Posted in: Medical Science News | Medical Research News | Disease/Infection News
Tags: Anxiety, Coronavirus, Coronavirus Disease COVID-19, covid-19, Depression, Evolution, Exercise, Fatigue, Frequency, Hospital, Laboratory, Lung Capacity, Medical Research, Medicine, Mental Health, Muscle, Oxygen, Pain, Research, Respiratory, SARS, SARS-CoV-2, Severe Acute Respiratory, Severe Acute Respiratory Syndrome, Syndrome, Walking
Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.
Source: Read Full Article